BiomeSense
Dylan is an experienced biomedical engineer with over 7 years experience in product development encompassing a variety of disciplines, including microfluidics, medical devices, and the microbiome. Prior to joining BiomeSense, he helped support and launch Augmenix’s flagship implantable hydrogel product that saw them acquired by Boston Scientific in 2018.
BiomeSense
BiomeSense is revolutionizing human microbiome research by creating novel tools to track, analyze, and store daily microbiome profiles of clinical trial participants, providing vastly more data than is possible with current tools, all for a fraction of the cost. This gives investigators far deeper insight into how the microbiome influences and is influenced by clinical interventions.